ARO-INHBE / Arrowhead - LARVOL DELTA

AROINHBE-1001: Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Phase classification: P1 ➔ P1/2 | N=78 ➔ 120

Enrollment change • Phase classification • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Select ARO-INHBE Preclinical Results (Businesswire) - "In a diet-induced obese (DIO) mouse model, hepatic INHBE silencing with siRNA led to a 19% suppression in body weight gain relative to vehicle controls. Treated mice exhibited improved body composition with a 22% reduction of fat mass while preserving lean mass. Treated mice also demonstrated a trend to improved glycemic control. Hepatic INHBE silencing in DIO mice enhanced catecholamine sensitivity, increasing lipid mobilization and oxidation, which was not associated with liver steatosis. In fact, treated animals showed less liver fat accumulation relative to saline controls...Dosing in the ARO-INHBE study was initiated in December 2024 with initial data possible by year end 2025."

P1 data • Preclinical • Metabolic Disorders • Obesity

AROINHBE-1001: Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity (Businesswire) - "Arrowhead Pharmaceuticals, Inc...today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity."

Trial status • Diabetes • Obesity

Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus (clinicaltrials.gov) - P1 | N=78 | Not yet recruiting | Sponsor: Arrowhead Pharmaceuticals

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Liver-Specific Silencing of INHBE with ARO-INHBE, an siRNA Therapeutic, for Metabolic Diseases (ADA 2024) - "ARO-INHBE effectively silences hepatic INHBE mRNA. In the DIO mouse model, liver-specific silencing of INHBE mRNA caused the suppression of fat mass gain, but preservation of LBM. A clinical lead siRNA targeting INHBE has been selected."

Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus